Chengbin Wu

Chengbin Wu

Company: EpiMab

Job title: Chief Executive Officer

Seminars:

A Novel Off-the-Shelf TCR Bispecific Platform for Cancer Immunotherapy 2:00 pm

Plug and play approach for making TCR engagers integrated with our clinical validated TCE technology Our approach was optimized from different design for best activity and IgG-like manufacturing properties The platform was validated by testing several TCR targets in vitro and in vivo with potent preclinical activityRead more

day: DAY ONE TRACK 2 B

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.